BACKGROUND: Alterations in lipid metabolism are considered among the potential factors contributing to the development and persistence of inflammation in acne vulgaris. However, data on blood levels of polyunsaturated fatty acids in these patients remain limited. AIM: This study aimed to characterize the profile of major omega-3 and omega-6 polyunsaturated fatty acids in the blood of patients with acne vulgaris and to assess the respective composite indices and fatty acid ratios. METHODS: This pilot cross-sectional analysis included 20 adults with clinically diagnosed acne vulgaris. Fatty acid analysis comprised the quantification of nine polyunsaturated fatty acids using gas chromatography with flame ionization detection. The results were expressed as percentages of total fatty acids. The whole-blood omega-3 index estimated erythrocyte membrane omega-3 index, arachidonic acid-to-eicosapentaenoic acid ratio, omega-6-to-omega-3 ratio, and linoleic acid-to-dihomo-gamma-linolenic acid ratio were calculated. RESULTS: Eicosapentaenoic acid levels below the laboratory reference interval were identified in 12 of 20 patients (60%). Elevated arachidonic acid levels were observed in 2 patients (10%). The arachidonic acid-to-eicosapentaenoic acid ratio exceeded the laboratory threshold value of 10.0 in all participants. The mean whole-blood omega-3 index was 4.05 ± 1.07%, while the mean estimated erythrocyte membrane omega-3 index was 4.20 ± 1.02%. Most of the other fatty acids analyzed were within the corresponding laboratory reference intervals. CONCLUSION: The fatty acid profile of the patients examined was characterized by a frequent reduction in eicosapentaenoic acid levels and a markedly elevated arachidonic acid-to-eicosapentaenoic acid ratio. The elevation of this ratio was primarily attributable to reduced eicosapentaenoic acid levels rather than increased arachidonic acid levels.
BACKGROUND: In women, acne may persist beyond adolescence or develop in adulthood. Androgen-dependent manifestations despite normal androgen levels may reflect variation in target-tissue receptor responsiveness, including CAG repeat length in the androgen receptor (AR) gene AIM: To evaluate the association between an operational marker of increased AR sensitivity, acne severity, and androgen-dependent conditions. METHODS: This single-center cross-sectional study included 101 women with papulopustular acne. AR CAG repeat length was determined in buccal epithelial samples by denaturing high-performance liquid chromatography. Analyses were based on the shorter allele, with ≤19 repeats considered a marker of increased AR sensitivity. Group I included 31 women without the marker and group II included 70 with it. Assessments included GAGS, sebometry, Ferriman–Gallwey score, Ludwig grade, and PCOS. Between-group comparisons used the Mann–Whitney U, Pearson’s chi-square, and Fisher’s exact tests; correlations were assessed using Spearman’s rank coefficient. RESULTS: Median GAGS scores were 32 [31–33.3] in group II versus 20.5 [14–24.3] in group I; median sebum output was 310 [287.5–340] versus 240 [230–250] μg/cm², and median Ferriman–Gallwey scores were 14 [0–19] versus 0 [0–0], respectively (p0.001). Ludwig grade II–III alopecia occurred in 50.0% of group II and was absent in group I. PCOS prevalence was 57.1% and 10.0%, respectively (p0.001). GAGS scores correlated with sebum production, alopecia severity, hirsutism, and total testosterone in both groups CONCLUSION: The marker of increased AR sensitivity was associated with greater acne severity, higher sebum production, and androgen-dependent conditions. The cross-sectional design does not permit causal inference
On June 16, 2026, the 1168th meeting of the Moscow Society of Dermatovenereologists and Cosmetologists named after A.I. Pospelov was held. The meeting was conducted in an in-person format in the conference hall of the V.A. Rakhmanov Dermatology Clinic. The meeting was attended by 130 people. One application for membership in the Moscow Society of Dermatovenereologists was submitted by a representative of N.I. Pirogov Russian National Research Medical University and was unanimously approved. The clinical section of the meeting included three presentations. The first presentation addressed the clinical efficacy of upadacitinib in the treatment of atopic dermatitis, alopecia totalis, and onychodystrophy (Sechenov University). The second presentation focused on diagnostic and therapeutic errors in the management of fungal infections of the skin and nails (Sechenov University). The third presentation described a case of successful treatment of onychomycosis with systemic terbinafine in a patient with systemic lupus erythematosus, antiphospholipid syndrome, and a history of stroke and hemiparesis («Health Is the Foundation of Everything» Medical Center [ZOV]). The scientific section of the meeting featured three reports. The first report focused on contemporary approaches to the treatment of infected dermatoses (Russian Medical Academy of Continuous Professional Education). The second report addressed the diagnosis of cutaneous diseases involving the face (Sechenov University). The third report concerned contemporary principles of treatment of acantholytic pemphigus (Sechenov University).
Rosai–Dorfman disease (sinus histiocytosis with massive lymphadenopathy) is a non-Langerhans-type histiocytic disorder characterized by histiocyte proliferation with emperipolesis. Rosai-Dorfman disease is a rarely diagnosed disease with variable clinical manifestations on the skin, in the lymphatic system, internal organs, requiring differential diagnosis with such nosologies as sarcoidosis, Langerhans cell histiocytosis, vasculitis, lymphoproliferative diseases (Hodgkin's lymphoma, non-Hodgkin's lymphomas). According to modern concepts, the disease can be associated with immunodeficiency states, including LRBA deficiency, and also demonstrate a variety of extranodal manifestations - from isolated axillary lymphadenopathy to destructive lesions of the bone structures of the nose with the formation of a recession of the nasal dorsum. Difficulties in differential diagnosis are associated with the similarity of certain histological and clinical features and molecular changes. Immunohistochemical testing with detection of the S-100 and CD163 markers, which are key diagnostic criteria for differentiating this pathology from other histiocytoses, is mandatory for confirming the diagnosis. This article describes Rosai-Dorfman disease in a 42-year-old man. The diagnosis was difficult for a dermatologist during an outpatient clinic visit. The initial clinical misdiagnosis (without histological or immunohistochemical examination) of benign lymphocytic keratosis led to an inappropriate management strategy. This clinical case demonstrates the challenges of differential diagnosis of Rosai-Dorfman disease in a dermatologist's routine practice. In the Russian Federation, systematic epidemiological data on the incidence of Rosai-Dorfman disease have been absent from the available literature in recent years. Existing publications consist of isolated clinical observations, due to the disorder's orphan status and the lack of a centralized federal registry of patients with this disease. International literature estimates the incidence to be less than 1 case per 1,000,000 population per year. Reporting each clinical observation is essential for accumulating data and optimizing the diagnosis and treatment of this rare disease.
Post-acne sequelae represent a clinically significant outcome of acne that may result in persistent structural skin changes and impaired quality of life. Despite the established heritability of acne, direct studies of genetic predictors of post-acne scarring remain limited, highlighting the need to systematically synthesize the available evidence. A systematic literature search was conducted in the PubMed/MEDLINE, Scopus, and Web of Science Core Collection databases from 2016 to 2026 in accordance with the PRISMA 2020 guidelines. Original human studies evaluating genetic factors associated with post-acne scarring and severe acne were included. Studies of candidate genes and genetic polymorphisms, genome-wide association studies (GWAS), as well as studies evaluating genetically determined alterations involved in extracellular matrix remodeling and inflammatory responses were considered. In addition, data from epigenetic, transcriptomic, miRNA, proteomic, and Mendelian randomization studies were taken into account when interpreting the findings. Direct studies identified associations between scarring and variants in genes involved in extracellular matrix remodeling, including MMP2 and TIMP2. The MMP2 -1306 CC genotype was predominantly associated with hypertrophic scarring, whereas the TIMP2 rs4789932 variant was associated with the risk and severity of scarring. Increased levels of miR-21, miR-150, and miR-223 were associated with a predisposition to atrophic scarring. Indirect evidence from genetic studies of acne indicates the involvement of genes related to inflammatory responses, steroidogenesis, oxidative stress, lipid metabolism, and extracellular matrix remodeling. GWAS further identified loci associated with pilosebaceous unit development, Wnt and TGF-β signaling, immune-inflammatory processes, and extracellular matrix remodeling. Epigenetic and proteomic studies further supported the potential role of gene expression regulation and individual mediators in the development of a severe acne phenotype. Post-acne scar formation is likely determined by a combination of the clinical severity of inflammation and interindividual, genetically determined variability in immune responses and tissue repair. Currently, no validated genetic markers for post-acne scarring risk are available for routine clinical use. Their validation requires large, multicenter, standardized studies accounting for morphological scar types and integrating genomic, transcriptomic, and epigenomic data.
